Daniel V. Catenacci, MD, University of Chicago

Articles by Daniel V. Catenacci, MD, University of Chicago

Is Frontline IO Therapy Appropriate in Gastric Cancer?

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Global Use of Frontline Therapy in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer